ATXS
Astria Therapeutics, Inc.
$12.58
+0.00
(+0.00%)
Mkt Cap
718.13M
Volume
3,057,633
52W Range
3.555-13.29
Sector
Healthcare
Beta
0.02
EPS (TTM)
-2.15
P/E Ratio
-5.32
Revenue (TTM)
706,000
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 500,000 | 0 | 0 | 0 | 0 |
| Net Income | (94.26M) | (72.89M) | (51.83M) | (194.91M) | (37.30M) | (26.29M) | (25.87M) | (27.36M) | (36.06M) | (32.63M) | (21.88M) | (18.12M) |
| EPS | -1.68 | -2.42 | -3.55 | -24.58 | -12.20 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 |
| Free Cash Flow | (81.54M) | (68.47M) | (43.62M) | (30.17M) | (32.52M) | (26.58M) | (23.45M) | (26.89M) | (33.32M) | (30.21M) | (20.64M) | (16.41M) |
| FCF / Share | -1.45 | -2.27 | -2.98 | -3.38 | -10.63 | -14.24 | -27.83 | -74.42 | -123.17 | -225.42 | -142.91 | -113.62 |
| Operating CF | (81.21M) | (68.44M) | (43.53M) | (30.15M) | (32.48M) | (26.57M) | (23.46M) | (26.84M) | (32.86M) | (29.79M) | (20.41M) | (16.37M) |
| Total Assets | 342.36M | 254.67M | 230.63M | 127.51M | 47.46M | 41.78M | 39.17M | 17.90M | 40.21M | 64.22M | 15.96M | 31.00M |
| Total Debt | 5.35M | 329,000 | 939,000 | 365,000 | 1.05M | 2.25M | 0 | 2.48M | 5.72M | 8.95M | 4.75M | 0 |
| Cash & Equiv | 59.82M | 175.53M | 20.52M | 86.51M | 24.93M | 9.90M | 15.29M | 16.37M | 23.60M | 62.78M | 14.67M | 30.47M |
| Book Value | 319.26M | 243.12M | 221.22M | 122.31M | 40.67M | 35.72M | 34.94M | 11.79M | 29.09M | 50.49M | (73.05M) | (52.18M) |
| Return on Equity | -0.30 | -0.30 | -0.23 | -1.59 | -0.92 | -0.74 | -0.74 | -2.32 | -1.24 | -0.65 | N/A | N/A |
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 706,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (31.64M) | (33.05M) | (33.71M) | (25.63M) | (24.53M) | (24.17M) | (19.93M) | (31.41M) | (17.73M) | (12.57M) | (11.19M) | (13.26M) |
| EPS | -0.55 | -0.57 | -0.58 | -0.45 | -0.43 | -0.43 | -0.38 | -0.86 | -0.63 | -0.45 | -0.40 | -0.66 |
| Free Cash Flow | (32.30M) | (36.65M) | (34.02M) | (17.36M) | (27.98M) | (17.10M) | (19.09M) | (30.25M) | (14.26M) | (10.70M) | (13.26M) | (10.70M) |
| FCF / Share | -0.56 | -0.63 | -0.59 | -0.31 | -0.50 | -0.30 | -0.37 | -0.83 | -0.51 | -0.38 | -0.47 | -0.58 |
| Operating CF | (32.30M) | (36.06M) | (34.02M) | (17.36M) | (27.96M) | (16.79M) | (19.09M) | (30.24M) | (14.26M) | (10.70M) | (13.25M) | (10.66M) |
| Total Assets | 271.87M | 281.92M | 310.39M | 342.36M | 361.64M | 367.99M | 378.81M | 254.67M | 193.86M | 207.05M | 218.24M | 230.63M |
| Total Debt | 4.46M | 4.77M | 5.06M | 5.35M | 5.64M | 5.79M | 168,000 | 329,000 | 488,000 | 643,000 | 794,000 | 939,000 |
| Cash & Equiv | 96.28M | 76.32M | 54.38M | 59.82M | 80.90M | 87.21M | 172.01M | 175.53M | 119.81M | 133.96M | 202.30M | 20.52M |
| Book Value | 233.25M | 260.51M | 289.29M | 319.26M | 341.65M | 347.08M | 367.74M | 243.12M | 184.48M | 200.40M | 211.36M | 221.22M |
| Return on Equity | -0.14 | -0.13 | -0.12 | -0.08 | -0.07 | -0.07 | -0.05 | -0.13 | -0.10 | -0.06 | -0.05 | -0.06 |
ATXS News
